U.S. Jury Orders AbbVie to Pay $3 Mln in AndroGel Retrial U.S. Jury Orders AbbVie to Pay $3 Mln in AndroGel Retrial

A U.S. jury ordered AbbVie to pay more than $3 million to a man who claimed the company misrepresented the risks of its testosterone replacement drug AndroGel, causing him to suffer a heart attack, though the jury did not find AbbVie strictly liable.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news